• SARANG V. BADKE Department of Pharmaceutical Quality Assurance, Progressive Education Society’s Modern College of Pharmacy, Sector -21, Yamunanagar Nigdi, pune-411044, Maharastra
  • KALYANI S. KAKAD Department of Pharmacognosy, Progressive Education Society’s Modern College of Pharmacy, Sector -21, Yamunanagar Nigdi, pune-411044, Maharastra
  • SARIKA S. MALODE Department of Pharmaceutics, NGSPM’S College of Pharmacy, Brahma Valley Education Campus, Anjaneri Nashik-422213


Remogliflozin etabonate, Vildagliptin, High Performance Thin Layer Chromatography, Validation, Forced Degradation



Within the scope of this investigation, an HPTLC technique for measuring the concentrations of Remogliflozin etabonate (REMO) and Vildagliptin (VIL) in a commercial product named REMO-V, which contains 100 mg of REMO and 50 mg of Vildagliptin (VIL), was developed.



It was necessary to evaluate the new approach for linearity, precision, specificity, and robustness in order to ensure that it operated properly. The chromatograms were created using a mobile phase containing Chloroform as follows: The concentrations of toluene, methanol, and n-butanol (4.5:4:1:0.5, v/v) were measured on a pre-coated TLC aluminium precoated plate (60F 254), and the absorbance at 233 nm was used to determine the amount of each component present. It was necessary to conduct forced degradation testing on bulk medicinal material in order to demonstrate the new method's capacity to demonstrate how stable and specific it is.



The Rf values for Remogliflozin etabonate (0.63), Vildagliptin (0.75), and Remogliflozin etabonate (0.63), respectively, were 0.63 and 0.75. On the REMO side, the linearity of the technique was found to be between 20 and 60 g/band; on the VIL side, it was found to be between 10 and 30 g/band. Having R2 values of 0.9939 for both REMO and VIL, it is clear that there is significant linearity in the way they interact with one another. These are the lower limits of detection and quantification for REMO, which were 0.09 for VIL and 0.38 for REMO, respectively, when compared to the upper limits of detection and quantification for VIL. The lower detection and quantification limits for VIL are also the same as for other pathogens. RSD was less than 2 percent in this study. Thus, the approach was shown to be accurate and exact for both interday and intraday accuracy, indicating that it is reliable. The amount of REMO or VIL that might be recovered is as follows: 98.7 percent to 101.27 percent, and 97.37 percent to 100.83 percent were the results.



It was discovered that the method for determining Remogliflozin and Vildagliptin was easy, accurate, and stable in both its pure form and its tablet dose form, and that it could be used to both (REMO-V, Glenmark, Ltd)


Download data is not yet available.


Mikhail N. Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus. Expert Opin Investig Drugs. 2015;24(10):1381-7. doi: 10.1517/13543784.2015.1061501. Epub 2015 Aug 14. PMID: 26288025.

Mohan V, Mithal A, Joshi SR, Aravind SR, Chowdhury S. Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy. Drug Des Devel Ther. 2020 Jun 24;14:2487-2501. doi: 10.2147/DDDT.S221093. PMID: 32612352; PMCID: PMC7322139.

Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008 Oct;327(1):268-76. doi: 10.1124/jpet.108.140210. Epub 2008 Jun 26. PMID: 18583547.

Vildagliptin. Available from: https://go.drugbank.com/drugs/DB04876.

Habib B, Mittha J. Quality Evaluation of Generic Products of Metformin and Vildagliptin Tablets. Asian J. Pharm. Anal. 2021;11(4):255-258.doi: 10.52711/2231-5675.2021.00043.

Baokar SB, Baokar S, Mulgund SV, Ranpise NS. Development and Validation of RP-HPLC Method for Simultaneous Estimation of Vildagliptin and Metformin. Res. J. Pharm. Dos. Forms Technol. 2013;5(52):95-98.

Bhatkar TV, Badkhal AV, Bhajipale NS. Stability indicating rp-hplc method development and validation for the estimation of remogliflozin etabonate in bulk and pharmaceutical dosage form. Int. J. Pharm. Res. 2020;12(4):160-169. doi: 10.31838/IJPR/2020.12.04.026.

Mohanasundaram.S, VA Doss, Haripriya G, Varsha M, Daniya S, Madhankumar. GC-MS analysis of bioactive compounds and comparative antibacterial potentials of aqueous, ethanolic and hydroethanolic extracts of Senna alata L against enteric pathogens. Int. J. Res. Pharm. Sci., 2017; 8 (1): 22 – 27.

Attimarad M, Nair AB, Sreeharsha N, Al-Dhubiab BE, Venugopala KN, Shinu P. Development and Validation of Green UV Derivative Spectrophotometric Methods for Simultaneous Determination Metformin and Remogliflozin from Formulation: Evaluation of Greenness. Int J Environ Res Public Health. 2021 Jan 8;18(2):448. doi: 10.3390/ijerph18020448. PMID: 33429964; PMCID: PMC7827813.

D. W. G. Harron, Technical Requirements for Registration of Pharmaceuticals for Human Use: The ICH Process, vol. 1994, no. October 1994. 2013.

Mohanasundaram.S, N.Rangarajan, V.Sampath, K.Porkodi, M.Pennarasi. GC-MS and HPLC analysis of Antiglycogenolytic and Glycogenic compounds in Kaempferol 3 – O – gentiobioside containing Senna alata L leaves in experimental rats. Translational Metabolic Syndrome Research., 2021; 4:10-17.

ICH Q1A(R2). International Conference on Harmonization (ICH). Guidance for industry: Q1A(R2) STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS. Ich Harmon. Tripart. Guidel., vol. 4, no. February, p. 24, 2003.

ICH. Guidance for industry Q1B photostability testing of new drug substances and products. Fed. Regist., vol. 62, no. November, pp. 27115–27122, 1996.



How to Cite

BADKE, S. V., KAKAD, K. S., & MALODE, S. S. (2022). HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY (HPTLC) METHOD DEVELOPMENT AND VALIDATION FOR DETERMINATION OF REMOGLIFLOZIN ETABONATE AND VILDAGLIPTIN IN BULK AND ITS TABLET FORMULATION. International Journal of Applied Pharmaceutics, 14. Retrieved from https://innovareacademics.in/journals/index.php/ijap/article/view/45552



Original Article(s)